- Strong Financial Performance: Kelun Pharma reported a net income of 1.80 billion yuan in the first half of the year.
- Significant Revenue: The company achieved a revenue of 11.83 billion yuan in the same period.
- Positive Market Sentiment: Analysts show strong confidence with 14 buy ratings, 2 hold ratings, and no sell ratings.
A look at Sichuan Kelun Pharmaceutical Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 4.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Sichuan Kelun Pharmaceutical is positioned for a positive long-term outlook in the pharmaceutical industry. With strong scores in Growth and Momentum, the company demonstrates promising potential for future expansion and market performance. Additionally, its high scores in Dividend and Resilience suggest stability and consistent returns for investors.
Sichuan Kelun Pharmaceutical Co., Ltd., known for manufacturing a variety of pharmaceutical products including infusion products, tablets, capsules, and traditional Chinese medicine, stands out for its solid overall performance across key factors. Investors may find the company appealing for its balanced approach to value, growth, and sustainability within the competitive landscape of the pharmaceutical sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
